Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hepatitis B vaccine recombinant - VBI Vaccines

Drug Profile

Hepatitis B vaccine recombinant - VBI Vaccines

Alternative Names: 3-Antigen HBV Vaccine; 3-Antigen Hepatitis B vaccine; 3-Antigen Prophylactic Hepatitis B Vaccine - VIB Vaccines; 3-Antigen Vaccine; 3A-HBV; Bio-Hep-B; Hepimmune; PreHevbri; PreHevbrio; Sci-B-Vac; Trivalent hepatitis B (HBV) vaccine

Latest Information Update: 19 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Weizmann Institute of Science
  • Developer VBI Vaccines
  • Class Hepatitis B vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B

Most Recent Events

  • 16 Apr 2024 VBI Vaccines in collaboration with Valneva plans to launch Hepatitis B vaccine recombinant for Hepatitis B (Prevention) in additional European Union countries in 2024
  • 14 Feb 2024 Brii Biosciences and VBI Vaccines enter into an agreement for transferring manufacturing technologies of VBI 2601 and Hepatitis B vaccine recombinant to additional manufacturing sites and expanding commercial supplies
  • 31 Dec 2023 Launched for Hepatitis B (Prevention) in Sweden (IM) before December 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top